The latest announcement is out from Pharma Mar SA ( (ES:PHM) ).
Pharma Mar, S.A. has released its annual report on the remuneration of its directors, detailing the compensation accrued in 2024 and planned for 2025. The report outlines the company’s remuneration policy, which aims to align with long-term interests and manage risks, while also considering shareholder feedback. The company has also introduced changes to its remuneration policy for 2025-2028 to ensure competitiveness and sustainability.
More about Pharma Mar SA
Pharma Mar, S.A. operates in the pharmaceutical industry, focusing on the development and commercialization of marine-derived drugs. The company is known for its innovative approach in oncology and other therapeutic areas, leveraging its expertise in marine biotechnology.
YTD Price Performance: 22.96%
Average Trading Volume: 1,486
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $1.8B
See more data about PHM stock on TipRanks’ Stock Analysis page.